News

Tedizolid met all primary and secondary efficacy outcomes designated by the FDA and EMA in the ESTABLISH 2 intravenous (IV) to oral transition study. Trius president and chief

POMS systems eliminate errors and minimize incidents to provide web based production management control system, consulting and project management services to large pharmaceutical and biologics companies. RoviSys MES

Both the companies will equally finance €10m as an investment in the innovation of the industrial platform at Genzyme Polyclonals site in Lyon – Gerland area. Transgene chairman

New chemical entity acotiamide hydrochloride hydrate that inhibits peripheral acetylcholinesterase activities was invented by Zeria. Acofide works by suppressing the degradation of acetylcholine that is believed to play

LIFEROL is a protein-based bio-replenishment product, which addresses the dual nature of immune metabolism: bioavailability of nutrients (immune-specific amino acids) and functional availability of immune revitalizers and minerals

Empagliflozin belongs to sodium glucose co-transporter-2 (SGLT2) inhibitor class of drugs, which blocks glucose re-absorption in the kidney and eliminates excess glucose through the urine. Boehringer Ingelheim metabolic-clinical

Phase 1 trial will assess the safety, pharmacokinetic and pharmacodynamic profile of BCX4161, a novel selective inhibitor of plasma kallikrein, in healthy volunteers. The study that is being

The research will focus on identifying and validating recurrent gene mutations that are potential targets for drug therapies. H3 Biomedicine president and CEO Markus Warmuth said genomic information

The multi-year research and development collaboration aims to apply gene therapy technology to modify a patient’s own T-cells genetically, known as chimeric antigen receptor (CAR) T-cells, to target